Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mebendazole in Stage 4 Colorectal Cancer
NCT03925662Phase 3Recruiting
- Start
- Apr 2019
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mebendazole in colorectal cancer (CRC). Primary endpoint: Number of patients with tumor response at 6 months. Started Apr 2019; status: recruiting.
02
Drugs
mebendazole
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03925662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03925662.